MULTIPLYING THE POSSIBILITIES

What this means for you

This application is over — abandoned 10 Nov 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

98473700

Mark type

Stylized text

Filed

28 Mar 2024

Abandoned

10 Nov 2025

Attorney of record

Joi A. White

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical substances for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutics for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutic agents for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy systems used to express therapeutic proteins in vivo for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biopharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; medicines for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; drugs for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; vaccines; in vivo cell therapies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells for medical purposes; gene therapy products, namely, lipid nanoparticle encapsulated nucleic acids; gene therapy preparations, in the nature of lipid nanoparticle encapsulated nucleic acids; gene therapy pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms for treatment of human diseases, disorders and conditions; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; in vivo cell engineering platforms for developing and engineering therapeutic cells, transient gene therapy, and durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; transient in vivo cell engineering platforms for durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders

Owner

• CAPSTAN THERAPEUTICS, INC., San Diego, CA, US

Prosecution history

• 20 Nov 2025 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
• 20 Nov 2025 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 29 Jul 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 29 Jul 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 07 May 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 07 May 2025 — NON-FINAL ACTION E-MAILED
• 07 May 2025 — NON-FINAL ACTION WRITTEN
• 08 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 08 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 08 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 08 Jan 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 08 Jan 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 10 Oct 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 10 Oct 2024 — NON-FINAL ACTION E-MAILED
• 09 Oct 2024 — ASSIGNED TO EXAMINER